Introduction {#Sec1}
============

Unlike pediatric acute lymphoblastic leukemia (ALL), which is curable in \> 90% of cases, adult ALL has historically had a dismal prognosis, with limited treatment options and cure rates less than 40% \[[@CR1], [@CR2]\], due in part to higher-risk disease features in this population and significant chemotherapy-associated toxicity. B cell ALL accounts for approximately 75% of ALL cases and has historically been associated with inferior outcome compared with T cell ALL \[[@CR2], [@CR3]\]. Among B cell ALL cases, Philadelphia chromosome (Ph)-positive ALL was also historically associated with very poor outcomes in the pre-tyrosine kinase inhibitor (TKI) era \[[@CR4]--[@CR6]\]. However, in recent years, major advances in our understanding of the disease pathophysiology and genomics have led to better disease stratification and prognostication, leading to the identification of high-risk subgroups, such as Ph-like ALL and early T cell precursor (ETP) ALL. Furthermore, the detection and monitoring of measurable residual disease (MRD) has become a standard of care not only in stratifying patients but also in guiding treatment strategies \[[@CR7], [@CR8]\]. Excitingly, the therapeutic arsenal of ALL, particularly B cell ALL, has been markedly expanded with the advent of TKIs targeting the BCR-ABL1 tyrosine kinase, novel antibody constructs, and chimeric antigen receptor (CAR) T cell therapy \[[@CR9]--[@CR16]\]. By following the pediatric model of multiagent combination regimens, many clinical trials have been initiated over the past 5 years to investigate the best approaches to optimize these novel therapies for adult ALL, all of which may help to reduce our reliance on hematopoietic stem cell transplantation (HSCT) in first complete remission (CR1). This comprehensive review will focus on the recent advances and current standards in the therapy of different subsets of adult ALL. We also discuss novel strategies to combine or sequence these various treatment modalities in adults with the ultimate goal of recapitulating the success that has been made in the pediatric population.

Philadelphia chromosome-negative ALL {#Sec2}
====================================

Important lessons have been learned with the advent of monoclonal antibodies (moAb) targeting CD22 (inotuzumab ozogamicin \[InO\]) and CD19 (blinatumomab), which have dramatically improved outcome of adults with relapsed/refractory (R/R) B cell ALL. This has generated much interest in introducing the novel agents earlier during the course of therapy in order to deepen remissions, prevent relapses, and prolong survival. We will first highlight the available data on novel agents in the R/R setting where they were first studied, and then will discuss new combination/sequencing strategies that are being explored in the frontline setting.

Relapsed/refractory setting {#Sec3}
---------------------------

The prognosis of R/R ALL has historically been dismal with complete remission (CR) rates of 20-40%, median overall survival (OS) of 6 months, and cure rates of \< 10% even with intensive salvage chemotherapy and HSCT \[[@CR17], [@CR18]\]. However, recent years have witnessed the introduction of novel agents, which showed significant survival benefit against standard therapies and expanded the armamentarium of ALL. The details of these single-agent studies have been reviewed extensively \[[@CR19]--[@CR21]\] and the data from pivotal trials are summarized in Table [1](#Tab1){ref-type="table"}. We will therefore focus primarily on emerging therapies and the ways these novel agents are being explored in innovative combinations. Table 1Landmark trials of novel agents approved as single agents in B cell ALLDrugStudy (phase)Mechanism of actionApproved indicationDate of FDA approval*N*Median age, years \[range\]CR/CRi rates, %MRD negativity, %Median RFS, monthsMedian OS, monthsReferenceInotuzomab ozogamicinIN-NOVATE (III)ADC anti-CD22R/R B cell ALLAugust 201710947 \[18-78\]81785.0 (PFS)7.7\[[@CR12]\]BlinatumomabTOWER (III)BiTE anti CD3/CD19R/R B cell ALLSeptember 201627141 \[18-80\]4476NR7.7\[[@CR13]\]BlinatumomabALCANTARA (II); Ph-positive ALL onlyBiTE anti CD3/CD19R/R B cell ALLJuly 20174555 \[23-78\]36886.77.1\[[@CR14]\]BlinatumomabBLAST (II)BiTE anti CD3/CD19MRD + ≥ 0.1% B cell ALLMarch 201811345 \[18-76\]N/A7854% at 18 months36.5\[[@CR15]\]TisagenlecleucelELIANA (II)Anti-CD19 CAR T cellsCD19+ B cell ALL that is refractory or in second or later relapse in patients up to 25 years of ageAugust 20177511 \[3-23\]8110059% at 12 months19.1\[[@CR16]\]*B cell ALL* B cell acute lymphoblastic leukemia, *Ph* Philadelphia chromosome, *ADC* antibody drug conjugate, *BiTE*; bi-specific T cell engager, *R/R* relapsed refractory, *CR* complete remission, *MRD* measurable residual disease, *N* number of patients who received the novel agent, *CR* complete remission, *CRi* complete remission with incomplete hematologic recovery, *N/A* non applicable, *RFS* relapse-free survival, *PFS* progression-free survival, *EFS* event-free survival, *NR* not reached, *OS* overall survival

### Inotuzimab ozogamicin monotherapy {#Sec4}

InO is an anti-CD22 moAb conjugated to the cytotoxic antibiotic calicheamicin. Based on promising phase I/II data, InO was compared to standard salvage chemotherapy in a phase 3 multicenter trial (INO-VATE) of 218 adult patients with CD22+ B cell ALL \[[@CR12], [@CR22], [@CR23]\]. The overall response and MRD negativity rates among responders were significantly higher with InO compared with chemotherapy (81% versus 29%, *P* \< 0.001, and 78% versus 28%, *P* \< 0.001, respectively). More patients who received InO were able to undergo HSCT (41% versus 11%; *P* \< 0.001). The median remission duration and progression-free survival were significantly longer with InO (4.6 versus 3.1 months; *P* = 0.03, and 5.0 versus 1.8 months; *P* \< 0.001, respectively). The median OS was 7.7 versus 6.7 months (*P* = 0.04). This was later confirmed with longer follow-up on 326 patients showing 2-year OS rates of 23% versus 10% (*P* = 0.01) in favor of InO \[[@CR24]\]. Predictors for better survival included achievement of CR, MRD negativity, and consolidative HSCT. Patients who achieved MRD negativity derived more benefits regardless of the number of prior therapies \[[@CR25]\]. InO was associated with more hepatotoxicity including veno-occlusive disease (VOD) but less hematologic and infectious complications compared with chemotherapy. VOD rate was 11% versus 1% with chemotherapy, mostly after HSCT and with use of dual-alkylator conditioning.

### Blinatumomab monotherapy {#Sec5}

Blinatumomab is a CD3/CD19 bispecific T cell engager moAb that has shown high efficacy in phase I/II studies in R/R B cell ALL, particularly in the setting of lower disease burden \[[@CR26], [@CR27]\]. The phase 3 multicenter international study TOWER subsequently showed superiority of blinatumomab compared to standard salvage chemotherapy in adult patients with heavily pre-treated R/R B cell ALL with higher CR rates (34% versus 16%; *P* \< 0.001), MRD negativity (76% versus 48%), and longer median OS (7.7 versus 4 months; *P* = 0.001) \[[@CR13]\]. The benefit was seen regardless of age, number of prior therapies, previous HSCT, or bone marrow blast percentage, but was more pronounced in first salvage (median OS 11.1 months versus 5.3 months). The two adverse events of interest were neurotoxicity and cytokine release syndrome (CRS), which were severe in 10% and 5% of cases, respectively.

### Novel combination studies {#Sec6}

The efficacy of these novel antibody constructs in ALL provides a rationale to combine either or both agents with lower intensity chemotherapy backbone with the goal of further improving outcomes. Table [2](#Tab2){ref-type="table"} summarizes the major novel combination trials in adult B cell ALL. Encouraging results have been shown with the combination of InO with mini-HCVD (which is a lower intensity version of the HCVAD regimen without doxorubicin) \[[@CR34]\]. Among 59 patients treated, the CR or CR with incomplete hematological recovery (CRi) rate was 78%, and the MRD negativity rate was 82%. The median OS and relapse-free survival (RFS) were 11 months and 8 months, respectively. Almost half of the patients were able to undergo HSCT, in which case the median OS was 25 months. The incidence of VOD was 15%, mainly in patients with prior or subsequent HSCT. When these results were compared with historical controls treated with single-agent InO, there was significant improvement in outcomes (CR/CRi rates 75% versus 63%, *P* = 0.02, and median OS 9.3 months versus 5.6 months, *P* = 0.02). The study has now been amended to investigate the addition of 4 cycles of blinatumomab following 4 cycles of the combination InO and mini-HCVD \[[@CR28]\]. This sequential strategy is potentially attractive as the addition of blinatumomab after debulking with mini-HCVD, and InO may lead to higher rates of MRD negativity and may also allow for the use of less chemotherapy and cumulative InO dose, ultimately reducing treatment-related mortality and improving long-term outcomes. In fact, the incidence of VOD was significantly reduced (from 15% to 5%) by using lower and fractionated dose of InO (first dose of 0.6 mg/m^2^ then 0.3 mg/m^2^ for each subsequent dose), and by spacing out the last dose of InO from HSCT by 3 to 6 months. In 62 patients treated in first salvage with mini-HCVD and InO, with or without blinatumomab, the CR/CRi and the 3-year OS rates were 92% and 42%, respectively. The 60-day mortality rate was 3% \[[@CR35]\]. These results represent remarkable improvement considering the historical median OS in R/R B cell ALL is only 6 to 12 months. Longer follow-up is needed to assess the relative contribution of blinatumomab to the regimen. Table 2Published trials of combination of novel agents in adult Ph-negative ALLRegimenPatient population*N*Median age \[range\], yearsInduction mortality, %CR/CRi rate, %MRD negativity, %HSCT rate, %CR duration, %OS rate, %Reference**R/R Ph-negative ALL**Mini-HCVD + InO ± blinatumomabPrimary refractory 13%CR1 duration \< 1 year 40%Prior HSCT 23%8435 \[9-87\]280804052% (2-year)39 (2-year)\[[@CR28]\]CVP + InO (SWOG 1312)Salvage 1: 44%Prior blinatumomab 38%Prior HSCT 19%4843 \[20-79\]261NR30NRMedian 10.9 months\[[@CR29]\]Venetoclax + navitoclaxB cell ALL 50%T cell ALL 50%Median prior therapies: 4Prior HSCT 14%Prior CAR T cells 17%3629 \[6-72\]856562544% (6-month)NR\[[@CR30]\]**Frontline Ph-negative older ALL**Mini-HCVD + InO ± blinatumomabAge ≥ 60 years6468 \[60-81\]09895576% (3-year)54 (3-year)\[[@CR31]\]Blinatumomab + POMP (SWOG 1318)Age \> 60 years3173 \[66-84\]066923DFS 56 (1-year)65 (1-year)\[[@CR32]\]**Frontline Ph-negative younger ALL**Sequential HCVAD + blinatumomabAge \< 60 years2738 \[18-59\]01009630RFS 76 (1-year)89 (1-year)\[[@CR33]\]*Ph* Philadelphia-chromosome; *ALL* acute lymphoblastic leukemia; *N* number, *CR1* first complete remission; *CR* complete remission; *CRi* complete remission with incomplete hematologic recovery; *MRD* measurable residual disease; *OS* overall survival; *EFS* event-free survival; *RFS* relapse-free survival; *mini-HCVD* mini-hyperfractionated cyclophosphamide, vincristine, dexamethasone; *InO* inotuzumab ozogamicin; *HSCT* hematopoietic stem cell transplant; *CAR* chimeric antigen receptor; *HCVAD* hyperfractionated cyclophosphamide, vincristine, Adriamycin, dexamethasone; *CVP* cyclophosphamide, vincristine, prednisone; *SWOG* South west oncology group; *POMP* prednisone, vincristine, methotrexate, mercaptopurine

### Other drugs of interest {#Sec7}

Preclinical studies have suggested that BCL-2 mRNA is highly expressed in multiple subtypes of ALL compared with normal pre-B controls, and that B-lineage ALL cells exhibit significant sensitivity to BCL-2 inhibition with venetoclax, resulting in rapid apoptotic cell death \[[@CR36], [@CR37]\]. Accordingly, the combination of venetoclax with lower-intensity chemotherapy is being evaluated in several prospective trials, including for untreated older patients (NCT03319901) or patients with R/R ALL (NCT03319901, NCT03504644, and NCT03808610). Navitoclax is another BH3 mimetic that inhibits BCL-2, BCL-XL, and BCL-W with encouraging antileukemic activity in ALL cells \[[@CR38]\]. Preliminary results of a small phase 1 study evaluating the combination venetoclax and navitoclax in 36 patients with heavily pre-treated R/R ALL (including prior HSCT and CAR T cells) have shown a 50% CR/CRi rates, with 60% MRD negativity among responders \[[@CR30]\].

Several moAbs targeting novel antigens, including CD25, CD123, and CD38, are in early development \[[@CR39]\]. ADCT-402 is an anti-CD22 antibody-drug conjugate that delivers the cytotoxic agent tesirine (SG3249), which may have less hepatotoxicity than InO. It has shown safety and antileukemic activity in ALL and is now being investigated in a dose-expansion study (NCT02669264) \[[@CR40]\]. Since high levels of regulatory T cells have been described as a mechanism of resistance to blinatumomab \[[@CR41]\], immune checkpoint inhibitors are being investigated in combination with blinatumomab in an effort to restore T cell proliferation and improve outcomes (NCT03160079, NCT02879695).

### Chimeric antigen receptor (CAR) T-cell therapy {#Sec8}

CAR T cell therapy targeting CD19 is novel immunotherapy that has shown high clinical efficacy in R/R B cell ALL. Autologous T cells are genetically modified to express antibodies directed against CD19+ leukemic cells. There are currently 4 generations of CARs based on the type and number of co-stimulatory domains, which improve their expansion and persistence in vivo \[[@CR42]\]. After lymphodepletion chemotherapy, T cells are infused into the patient in order to exert their direct cytotoxic effect and harness both innate and adapt immunity. The single infusion of tisagenlecleucel, a CD19 CAR T cell therapy, was evaluated in a pivotal phase 2 multicenter study of 75 children and young adults with R/R CD19+ B cell ALL, 61% of whom had received prior HSCT \[[@CR16]\]. Among evaluable patients (80% of enrolled patients), the CR rate was 81%, all of which were MRD-negative. CAR T cells persisted for up to 20 months in the blood. The 18-month RFS and OS rates were 66% and 70%, respectively \[[@CR43]\]. Adverse events of interest were CRS and neurotoxicity, occurring in 70% and 40%, respectively. Although, these toxicities are often of severe intensity, they are generally manageable with supportive therapy including the anti-interleukin 6 antibody, tocilizumab (only for CRS), and dexamethasone. This trial has led to the approval of tisagenlecleucel for R/R CD19+ B cell ALL after 2 prior lines of therapy or refractory to first-line therapy in patients up to 25 years of age.

Similar results were obtained with another CD19 CAR-T cell construct (containing CD28 and CD3 zeta chain co-stimulatory domains) from the Memorial Sloan Kettering Cancer Center in a phase 1 trial of 53 patients \[[@CR44]\]. Notably, this trial included adult patients, and 15% were above 60 years of age. Higher tumor burden (bone marrow blasts \> 5% or extramedullary disease) was associated with inferior outcomes (median OS 12 versus 20 months) and higher rates of CRS and neurotoxicity. The better efficacy and tolerability of CAR T cells in the context of low burden disease has generated interest in their wider use in patients with MRD-only disease as a potentially curative approach. A phase 3 trial is planned to compare tisagenlecleucel with blinatumomab or InO in adult patients with R/R B cell ALL (NCT03628053).

Frontline therapy of older adults {#Sec9}
---------------------------------

Adults older than 60 years of age account for 20% of ALL cases and 50% of all ALL-related deaths across all age groups \[[@CR45]\]. This striking difference between incidence and disease-specific mortality highlights the poor outcome and high unmet need of this older population. Survival rates have been historically dismal; less than 20% across many study groups primarily due to a higher risk of adverse-risk biology and comorbidities that may preclude intensive curative modalities (Table [3](#Tab3){ref-type="table"}) \[[@CR45]--[@CR49]\]. Efforts made to modify intensive chemotherapy in order to decrease induction mortality and improve remission rates have resulted in sub-optimal success. For instance, in one retrospective study, despite dose reduction of cytarabine, the rates of induction mortality and death in CR in older patients treated with HCVAD regimen (hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine) were 10% and 35%, respectively \[[@CR1], [@CR46]\]. Table 3Challenges in treating older patients with ALL**Clinical factors** Decreased performance status Increased number of comorbidities Decreased organ function Polypharmacy Frequent dose reductions, delays, or omission Higher risk of adverse events (infections, neurotoxicity, secondary malignancies)**Biological factors** Increased incidence of adverse-risk karyotype (e.g., low hypodiploidy/near-triploidy, t(9;22), t(4;11), complex cytogenetics) Lower incidence of favorable-risk karyotype (hyperdiploidy, t(12;21), ETV6-RUNX1) Higher incidence of adverse risk molecular signatures (Philadelphia chromosome-like, TP53 mutation)**Social factors** Inadequate caregiver and/or social support Transportation/travel difficulties to tertiary centers**Other factors** Perceived lack of benefit of receiving anti-leukemia therapy rather than supportive/hospice care

In the R/R setting, blinatumomab and InO have improved remission and survival rates irrespective of age (\> 60 years and \< 60 years) compared with standard salvage chemotherapies \[[@CR12], [@CR13]\]. Due to their acceptable toxicity profile and significant activity, there has been much interest in combining them with lower-intensity chemotherapy in the frontline setting in order to decrease toxicity and improve outcomes of older patients. For example, InO has been successfully combined with mini-HCVD with no induction mortality and with high clinical efficacy \[[@CR50]\]. A similar combination of InO with lower intensity chemotherapy for older patients with Ph-negative B cell ALL is also being investigated in the EWALL-InO study (NCT03249870).

Similar to the R/R setting, the sequential combination of InO mini-HCVD followed by blinatumomab has been investigated in a phase 2 study in older untreated patients with promising results \[[@CR31]\]. Among 64 patients treated with mini-HCVD and InO, with or without blinatumomab, the median age was 68 years (range 60--81 years) with 42% being older than 70 years. The CR rate was 98%, and the MRD negativity rate was 95%. The 3-year CR duration and OS rate were 76% and 54%, respectively. A propensity match score showed significant improvement compared to the historical 3-year OS rate of 32% with HCVAD in this older population (*P* = 0.007). Although no early death occurred in induction, the rate of death in remission was 33% and was significantly higher in those age ≥ 70 years compared to those age 60-69 years (50% versus 22%, respectively; *P* = 0.02). In order to mitigate the significant toxicity in this older population, the protocol has been amended to decrease the number of mini-HCVD plus InO cycles from four to two, and to replace POMP maintenance with blinatumomab monotherapy for patients ≥ 70 years of age.

The SWOG 1318 study evaluated chemotherapy-free induction and consolidation with blinatumomab (total of 4-5 cycles) followed by POMP maintenance (prednisone, vincristine, methotrexate, and 6-mercaptopurine). Thirty-one patients with a median age of 73 years (range 66-84) were treated. Early results showed no induction death, CR rate of 66% (among them 92% with negative MRD), and 1-year RFS and OS rates of 56% and 65%, respectively \[[@CR32]\]. A planned phase 2 trial will investigate the combination of InO with blinatumomab in older untreated patients or R/R B cell ALL (NCT03739814).

Frontline therapy of younger adults {#Sec10}
-----------------------------------

In order to further improve outcomes of younger patients with newly diagnosed B cell ALL, a phase 2 trial is investigating the sequential use of HCVAD and blinatumomab with promising safety and efficacy \[[@CR33]\]. The regimen consists of 4 cycles of HCVAD followed by 4 cycles of blinatumomab. Earlier incorporation of blinatumomab after 2 cycles of chemotherapy is allowed for patients at high risk for early relapse, particularly those with Ph-like ALL, complex karyotype, t(4;11), low-hypodiploidy/near triploidy, or persistent MRD. Four cycles of blinatumomab are also incorporated in the 12 cycles of POMP maintenance (each 3 cycles of POMP followed by 1 cycle of blinatumomab) for a total of 18 months of maintenance therapy. Among 27 patients treated (median age 27 years \[range 18-57\]), the CR and MRD negativity rates were 100% and 96%, respectively, with no induction death. One-third of patients underwent HSCT for high-risk features. With a median follow-up of 17 months, 93% are alive; one patient died after HSCT of a transplant-related complication, and one died of sepsis during re-induction after relapse. The 1-year RFS and OS rates were 76% and 89%, respectively. A randomized phase 3 trial is currently evaluating chemotherapy with or without blinatumomab for ALL in the frontline setting and may provide more definitive evidence about the benefit of early incorporation of blinatumomab (NCT02003222).

Philadelphia chromosome-positive ALL {#Sec11}
====================================

The Philadelphia chromosome, formed by reciprocal translocation t(9;22), is the most common chromosomal abnormality in adult ALL, with increasing incidence with age, reaching up to 50% in patients above 60 years of age \[[@CR51], [@CR52]\]. Historically, outcomes have been poor for patients with Ph-positive ALL with long term survival of less than 20% \[[@CR4]--[@CR6]\]. The addition of TKIs to chemotherapy has revolutionized therapy of patients with Ph-positive ALL, and is now standard of care. A summary of published frontline trials for Ph-positive ALL is provided in Table [4](#Tab4){ref-type="table"}. The goal of therapy in Ph-positive ALL is not only to achieve and maintain CR, but to achieve complete molecular response (CMR) early in the treatment course. In one study, achievement of CMR within 3 months of treatment was the only independent prognostic factor for OS and identified patients who may have excellent long term survival without HSCT (4-year OS: 66%), thus potentially identifying patients in whom HSCT in CR1 may be safely deferred \[[@CR66], [@CR67]\]. The optimal duration of TKI therapy is not well-established but is often indefinite (in the absence of unacceptable toxicity) unless allogeneic HSCT is performed, after which most experts recommend post-HSCT TKI maintenance for approximately 1-2 years \[[@CR68]--[@CR71]\]. A small case series from the MD Anderson Cancer Center (MDACC) showed that TKI maintenance discontinuation outside of HSCT may be cautiously feasible in a subset of patients with deep and prolonged molecular remissions experiencing significant toxicity (e.g., CMR of least 5 years) \[[@CR68]\]. In this retrospective analysis, 9 patients discontinued TKI maintenance (due to side effects), all of whom were in deep molecular response after a median of 70 months of therapy. After a median follow-up of 49 months, 3 molecular relapses occurred at a median of 6 months and the 4-year treatment-free remission rate was 65% (with all patients regaining molecular response after resuming TKI). Table 4Published frontline trials of TKI-based regimens in adult Ph-positive ALLTKI*N*Median age, years \[range\]CR rate, %Induction mortality, %Overall CMR rate, %HSCT rate, %RFS rate, %OS rate, %Reference**Intensive chemotherapy + TKI** Imatinib5451 \[17-84\]932453043 (5-year)43 (5-year)\[[@CR10]\] Imatinib16942 \[16-64\]925NR7250 (4-year)38 (4-year)\[[@CR53]\] Dasatinib7255 \[21-80\]964601744 (5-year)46 (5-year)\[[@CR54]\] Nilotinib9047 \[17-71\]919867072 (2-year)72 (2-year)\[[@CR55]\] Ponatinib8646 \[21-80\]1000862184 (3-year)78 (3-year)\[[@CR56], [@CR57]\]**Lower-intensity chemotherapy + TKI** Imatinib13549 \[18-59\]9892862EFS 37 (5-year)46 (5-year)\[[@CR11]\] Dasatinib7169 \[59-83\]9642410EFS 28 (5-year)36 (5-year)\[[@CR58]\] Dasatinib6042 \[19-60\]1000194249 (3-year)58 (3-year)\[[@CR59]\] Nilotinib7965 \[55-85\]942581642 (4-year)47 (4-year)\[[@CR60]\] Nilotinib6047 \[18-59\]982NR; MMR 805285 (1-year)96 (1-year)\[[@CR61]\]**Steroids + TKI** Imatinib3069 \[61-83\]10004NR48 (1-year)74 (1-year)\[[@CR62]\] Dasatinib5354 \[24-77\]1000153451 (2-year)69 (2-year)\[[@CR63]\] Ponatinib4269 \[27-85\]95046NRNR88 (1-year)\[[@CR64]\]**Blinatumomab + TKI** Dasatinib6355 \[24-82\]972361988 (1-year)95 (1-year)\[[@CR65]\]*TKI* tyrosine kinase inhibitor, *N* number, *CR* complete response, *CMR* complete molecular response, *NR* not reported, *MMR* major molecular response, *HSCT* allogeneic hematopoietic stem cell transplant, *RFS* relapse-free survival, *EFS* event-free survival, *OS* overall survival

Intensive chemotherapy + TKI {#Sec12}
----------------------------

The TKI era in Ph-positive ALL started when the addition of imatinib to intensive chemotherapy improved CR rates to \~ 95% and long term OS rates to 40-50%, which compared very favorably to the historical long term OS of \< 10-20% in the pre-TKI era \[[@CR9], [@CR10], [@CR53], [@CR72], [@CR73]\]. Dasatinib is a second-generation TKI that was combined with HCVAD regimen in two phase 2 trials, showing improvement upon imatinib data, with a CR rate of 96%, CMR rate of 56% and 3-year DFS and OS rates of 60-62% and 64-69%, respectively \[[@CR9], [@CR54], [@CR74]\]. A landmark analysis of the SWOG study of HCVAD plus dasatinib in younger adults with Ph-positive ALL showed benefit for HSCT in CR1 in terms of RFS (*P* = 0.038) and OS (*P* = 0.037); however, MRD data were not available so it is not clear whether any subgroup preferentially benefited from consolidative HSCT. Nilotinib plus chemotherapy has also been studied with similarly promising results (2-year OS rate: 72%) \[[@CR55]\].

*T315I* mutations of the *ABL1* kinase domain have been described in up to 75% of patients who relapse after treatment with first- or second-generation TKIs \[[@CR58], [@CR74]\]. This has led to interest in using ponatinib, a third-generation TKI with high potency and activity against this common resistance mutation \[[@CR58], [@CR74], [@CR75]\]. The addition of ponatinib to HCVAD regimen has been tested in a phase 2 single-arm study with encouraging results. Initially, a ponatinib dose of 45 mg daily was used throughout the study. However, due to the increased incidence of severe vascular events, including 2 deaths related to ponatinib, the protocol was amended to reduce the dose of ponatinib to 30 mg daily after achievement of CR, and to 15 mg daily after achievement of CMR, with improved safety \[[@CR56], [@CR57], [@CR76]\]. In the most recent update, 86 patients with a median age of 46 years have been treated \[[@CR57]\]. The 3-month CMR rate was 74%, and the cumulative CMR rate was 84%. Only 18 patients (21%) underwent HSCT in CR1. With a median follow-up of 44 months, 71% of patients remain alive in remission, and only 3 relapses occurred while on ponatinib. The 5-year event-free survival (EFS) and OS rates were 68% and 74%, respectively. It is worth noting that while none of the TKIs have been compared head-to-head in Ph-positive ALL, one meta-analysis and one propensity-matched score analysis both showed superiority of ponatinib-based regimens over regimens containing earlier generation TKIs \[[@CR77], [@CR78]\]. Depth of remission, EFS, and OS rates all favored ponatinib.

Lower-intensity chemotherapy + TKI {#Sec13}
----------------------------------

In order to decrease treatment-related toxicity, lower intensity regimens have been investigated in Ph-positive ALL, mainly in older patients who are unfit for intensive chemotherapy \[[@CR11], [@CR58], [@CR60], [@CR64]\]. Several single-arm trials have evaluated the combination of dasatinib or nilotinib with low-dose chemotherapy in older patients (\> 55 years of age). In the EWALL-PH-01 trial, which used dasatinib, the CR rate was 96%, and the major molecular response (MMR) rate was 65% \[[@CR58]\]. However, long-term outcomes were not optimal; the 5-year RFS and OS rates were only 28% and 36%, respectively. Additionally, a *T315I* mutation was present in most relapses (75%). Nilotinib yielded comparable results to dasatinib when combined with similar backbone chemotherapy in the EWAL-PH-02 trial \[[@CR60]\]. The CR rate was 94%, and the 4-year RFS and OS were 42% and 47%, respectively.

Lower-intensity regimens are also being evaluated in younger patients, with the goal of reducing reliance on chemotherapy, and thus decreasing treatment-related toxicity. Notably, one randomized trial (GRAAPH-2005) compared the combination of imatinib with either HCVAD or lower-intensity version of the HCVAD (vincristine + prednisone in even cycles, thus, omitting doxorubicin and cyclophosphamide, while keeping methotrexate and cytarabine in odd cycles at standard dosing) in younger patients (median age 47 years). There was no statistically significant difference in 5-year EFS and OS rates between higher-intensity and lower-intensity regimens (42.2% versus 32.1%, *P* = 0.13, and 48.3%, versus 43.0%, *P* = 0.37, respectively) \[[@CR11]\]. Importantly, this study showed that the combination of lower-intensity chemotherapy plus TKI may lead to similar long-term outcomes, and lower toxicity compared with intensive chemotherapy-based approach. However, there were a few limitations to the trial including the higher-than-expected 60-day mortality with HCVAD regimen (9%) and the intermittent dosing of imatinib (2 weeks on, 2 weeks off), which may not be optimal for continuous suppression of BCR-ABL1 \[[@CR79]\]. The combination of dasatinib with prednisone was evaluated in younger patients in the GIMEMA LAL1509 trial (median age: 42 years). Patients who did not achieve CMR by day 85 (82% of the study population) subsequently received subsequent chemotherapy, with or without HSCT, whereas those who achieved CMR continued with dasatinib alone. Using this risk-adapted treatment approach, the 3-year OS rate was 58%. Those who achieved early CMR (18% of the cohort) and thus received no subsequent chemotherapy, had a very promising OS rate of 75% at 30 months. This suggests that early, deep response to lower-intensity therapy may allow for selection of patients who can have excellent outcomes with chemotherapy-free regimens. Similarly, in the phase II CALGB 10701 study, which combined dasatinib with prednisone in induction then added minimal chemotherapy in consolidation, high CR rates were seen (86%), allowing a third of patients to undergo allogeneic HSCT, among whom no relapses occurred at a median follow up of 23 months \[[@CR80]\]. An ongoing phase 2 study at MDACC is investigating the combination of mini-HCVD with ponatinib and sequential blinatumomab in the frontline setting.

Steroids + TKI {#Sec14}
--------------

Several trials also evaluated the frontline combination of TKIs (most at a higher dose) with steroids in elderly frail patients with excellent CR rates and minimal toxicity \[[@CR59], [@CR62]--[@CR64]\]. However, deep responses were, not unexpectedly, rarely attained, remissions were short, and relapses were common resulting in poor long-term survival. The rates of CMR appear to be higher with successive generations of TKIs (e.g., 46% with ponatinib, 18% with dasatinib, and 4% with imatinib) \[[@CR59], [@CR62]--[@CR64]\]. Among 42 older patients treated with ponatinib and steroids (median age 68 \[range 27-85\]), the CMR and 1-year OS rates were 46% and 88%, respectively. Toxicity was high with 45 mg dosing and only 15/42 patients were still receiving this dose at week 24. One death was related to ponatinib \[[@CR64]\]. While encouraging for this older population, novel lower-intensity strategies are needed to improve the CMR rate, as this has been shown to translate to superior long-term outcomes \[[@CR67]\].

Blinatumomab {#Sec15}
------------

Blinatumomab has shown safety and efficacy in heavily pre-treated R/R Ph-positive ALL in a single-arm multicenter phase 2 trial \[[@CR14]\]. Among 45 patients treated (50% with prior exposure to ponatinib, 44% with prior HSCT, and 27% with *T315I* mutation), the CR/CRi rate was 36%, with 88% of responders achieving MRD negativity. Responses were observed regardless of *T315I* mutation status. Half of patients were able to undergo HSCT, and the median OS was 7.1 months.

The combination of blinatumomab with TKI (mainly ponatinib) has been shown to be safe and effective in a small case series of 15 patients from MDACC with 50% CR rate and 75% molecular response \[[@CR81]\]. The GIMEMA group has recently presented early results from D-ALBA, the first trial investigating the sequential use of TKI/steroid (in induction) and blinatumomab (in consolidation) \[[@CR65]\]. Sixty-three patients have been treated thus far with this regimen of prednisone, dasatinib, and blinatumomab. The CR rate was 98%, and the 1-year DFS rate was 88%. Deep molecular response increased throughout therapy (29% after induction, 60% after 2 cycles of blinatumomab, and 80% after 4 cycles). Notably, *T315I* mutation was noted in 6/15 patients with rising MRD in the induction phase, all of which were cleared after blinatumomab. Several similar trials are evaluating the combination of blinatumomab with dasatinib (NCT02143414, NCT04329325) and ponatinib (NCT03263572) in both frontline and R/R settings.

Inotuzumab ozogamicin {#Sec16}
---------------------

The combination of InO with bosutinib is being evaluated in a phase 1/2 trial in R/R Ph-positive ALL (NCT02311998). Patients with *T315I* mutation are excluded. Early results have been presented on 14 patients with CR/CRi and CMR rates of 79% and 55%, respectively \[[@CR82]\]. The median EFS and OS were 8.1 and 8.2 months, respectively. Although there is a theoretical concern for overlapping hepatic toxicity with the combination of InO and ponatinib, studies evaluating this combination are warranted given the high efficacy of both of these agents in ALL.

Philadelphia-chromosome like ALL {#Sec17}
================================

Among B cell ALL, Ph-like ALL is a newly identified aggressive subtype that is characterized by a genomic signature similar to Ph-positive ALL, however, without the presence of *BCR-ABL1* rearrangement \[[@CR83]--[@CR85]\]. The incidence of Ph-like ranges from 15% in pediatric ALL to \> 50% among young adults of Hispanic ethnicity \[[@CR86]\]. Prognosis is poor with an estimated survival of \< 30% \[[@CR87]\]. Similar to Ph-positive ALL, *IKZF1* deletions are commonly found in Ph-like ALL (\~ 70%) \[[@CR85], [@CR86]\]. More than half of patients have cytokine receptor-like factor 2 (CRLF2) rearrangement, among whom, 50% have concomitant activating mutations of Janus kinases (JAK1, JAK2, and JAK3). In patients without CRLF2 rearrangement/overexpression, genomic profiling may identify a variety of kinase-activating alterations, including rearrangements in *ABL* class genes (e.g., *ABL1*, *ABL2*, *CSF1R*, *PDGFRA*, and *PDGFRB*), *EPOR*, *JAK2*, and mutations involving *FLT3*, *IL7R*, or *SH2B3*, among others \[[@CR88]\]. Adult patients with Ph-like ALL treated with conventional cytotoxic regimens, not only have approximately half the rate of MRD negativity, but their outcomes remain poor even when MRD negativity is achieved \[[@CR89]\]. Whether the addition of novel agents (InO or blinatumomab) or HSCT is superior to intensive chemotherapy remains uncertain and this represents an area of active research. Notably, there may be a role for TKIs or other targeted therapies in a subset of patients with targetable fusions (e.g., dasatinib for *ABL* gene alterations; NCT02420717) \[[@CR87], [@CR90]\]. Given the prevalence of JAK/STAT alterations in Ph-like ALL, a few studies of ruxolitinib combination with chemotherapy are ongoing (NCT03117751, NCT02420717), although it is uncertain how beneficial this approach may be, as preclinical data suggests that lymphoblasts may not be dependent on continued activation of this pathway for maintenance of the malignant phenotype \[[@CR91]\].

T-cell ALL {#Sec18}
==========

T cell ALL is generally treated with the same chemotherapy regimens used for B-cell ALL with relatively similar response, except in ETP ALL, where response rates and outcomes are significantly worse \[[@CR2]\]. The development of novel therapies for T cell ALL has lagged behind advancements seen in B cell ALL with no applicability of commercially available moAbs and CAR T cells, which may translate into inferior survival. Salvage options are limited, consisting mainly of conventional chemotherapy and HSCT among responders. Nelarabine is a T cell-specific purine analog that has shown efficacy in R/R T cell ALL (CR rates 30-40%), and has allowed some patients to undergo HSCT and achieve long-term survival \[[@CR92]--[@CR94]\]. This has warranted its exploration in the frontline setting in order to improve outcomes. In the pediatric experience, the addition of nelarabine to frontline Augmented Berlin-Frankfurt-Munster chemotherapy regimen (ABFM) in patients with T cell ALL up to 31 years of age improved the 4-year DFS rate from 83.3% with ABFM alone to 88.9% with the combination, *P* = 0.00332 \[[@CR95], [@CR96]\]. However, these results have not been replicated in adults yet. A single-arm phase 2 study from MDACC of nelarabine combined with frontline HCVAD regimen in 67 patients failed to improve CR duration or OS rates compared to historical controls treated with HCVAD alone \[[@CR97]\]. This study has now been amended to include the incorporation of nelarabine, peg-aspragainase, and venetoclax into the HCVAD regimen. Additionally, the combination of nelarabine with standard intensive induction chemotherapy is being evaluated in a phase 2 randomized trial (UKALL14) in the frontline treatment of adults with T cell ALL.

ETP ALL is a distinct and aggressive subtype of T cell ALL characterized by CD1a(−), CD8(−), CD5(−/dim; \< 75% expression), and positivity for one or more stem cell or myeloid antigens \[[@CR98]\]. ETP ALL has been associated with lower frequency of *NOTCH1* mutation, lower response to therapy, higher rates of post-induction MRD positivity, and inferior survival compared with non-ETP ALL \[[@CR89], [@CR98]--[@CR101]\]. Interestingly, ETP cells have been shown to be preferentially sensitive to the BCL-2 inhibitor, venetoclax \[[@CR102]\]. The addition of venetoclax to lower-intensity chemotherapy in older adults with newly diagnosed ALL has yielded encouraging early results in interim results of 10 patients treated (3 with T cell ALL, including 2 with ETP ALL) with 90% CR/CRi and MRD negativity rate (for both) \[[@CR103]\]. The combination of venetoclax and navitoclax may also be particularly promising in this subgroup.

Special populations/considerations {#Sec19}
==================================

Adolescents and young adults (AYA) {#Sec20}
----------------------------------

According to the National Institute of Health, the AYA population is defined as patients between 16 and 39 years of age \[[@CR104]\]. Several prospective trials that utilized pediatric-inspired intensive regimens in AYA patients have yielded CR rates in 85-90% and long-term EFS and OS in the 60-70% range \[[@CR105]--[@CR112]\]. Pediatric protocols employ extensive use of asparaginase, which can be associated with significant toxicity in adults (e.g., anaphylaxis, pancreatitis, hepatotoxicity, thrombosis, and coagulopathy), making them more challenging to deliver to older patients. The feasibility and efficacy of a pediatric-inspired regimen dedicated specifically for AYA patients has been recently demonstrated in a prospective multicenter study (CALGB 10403) \[[@CR113]\]. The induction mortality was 3% and the CR rate was 89%. The 3-year EFS and OS rates were 59% and 73%, respectively, which are improved compared to historical controls (48% and 55%, respectively). The investigators at MDACC compared a pediatric-inspired regimen (ABFM, which contains daunorubicin, vincristine, asparaginase, steroids, cytarabine, and methotrexate) with the HCVAD regimen in AYA patients in a non-randomized study \[[@CR114]\]. The 5-year OS rates were 60% in both groups. As expected, hepatic, pancreatic, and thrombotic toxicities were more common with ABFM, whereas myelosuppression and infectious complications were more common with HCVAD. Induction mortality was low in both groups (1%). These findings appear similar to the CALGB 10,403 results and support HCVAD as an acceptable regimen for AYA patients. In the absence of a randomized study comparing both regimens in the AYA population, it is important that practitioners adopt the protocol that matches their institution's comfort level, and that they adhere to the protocol in its entirety, as these are key factors in achieving superior outcomes. More recently, the superior survival seen among patients with negative MRD has generated interest in integrating novel therapies early during induction in order to achieve deeper remission and improve cure rates. This is currently being investigated in the Alliance A041501 trial, which is adding InO to the CALGB 10403 backbone in AYA patients with newly diagnosed Ph-negative B cell ALL (NCT03150693).

CD20-positive B-cell ALL {#Sec21}
------------------------

CD20 is a B cell marker that is expressed in 30-50% of precursor B cell ALL \[[@CR115]\]. The addition of an anti-CD20 monoclonal antibody (moAb) to multiagent chemotherapy is a standard of care for younger patients (\< 60 years old) with CD20+ B cell ALL (defined as CD20 expression ≥ 20%) \[[@CR116]--[@CR118]\]. This was first assessed in a prospective trial at MDACC where 12 doses of rituximab added to HCVAD improved outcome of patients who were younger than 60 years in terms of CR duration (67% versus 40%; *P* \< 0.002) and OS rates (3-year OS 75% versus 47%; *P* = 0.003), compared with historical patients treated with HCVAD alone \[[@CR118]\]. No benefit was observed in older patients, which was attributed to the high rate of myelosuppression-related deaths in this group. These results were later confirmed in the GRAALL-2005/R randomized study of adults younger than 60 years, which showed improvement in the 2-year EFS and OS rates from 52 to 65% (*P* = 0.038), and from 64 to 71% (*P* = 0.095; with censoring for HSCT, *P* = 0.018), respectively \[[@CR117]\]. Of note, there was no increase in adverse events in patients receiving rituximab. Although there is no definitive evidence for the benefit of rituximab in older adults, it is reasonable to add it to frontline regimens in older adults given its manageable safety profile. In Burkitt leukemia/lymphoma, in which CD20 is universally and strongly expressed, the addition of rituximab to intensive chemotherapy backbone has improved survival and is a standard of care \[[@CR116], [@CR119], [@CR120]\].

Ofatumumab is a second-generation anti-CD20 antibody with higher complement-dependent cytotoxicity and slower dissociation rate compared to rituximab \[[@CR121]\]. Ofatumumab has been evaluated in a phase 2 study in combination with HCVAD in frontline B cell ALL with any level of CD20 expression (i.e., ≥ 1%) \[[@CR122]\]. The clinical benefit was seen across all CD20+ subgroups (\< 20% and \> 20%). These results appear similar to historical cohorts treated with HCVAD + rituximab with 4-year EFS and OS rates of 59% and 68%, respectively. Therefore, ofatumumab is a reasonable option for CD20+ B cell ALL, especially with low level of CD20 expression---a population where rituximab has not been extensively studied. No clinical trials exist yet on obinutuzumab in ALL.

Central nervous system (CNS) prophylaxis {#Sec22}
----------------------------------------

Despite the relatively low incidence of CNS disease at presentation in ALL (5-10%), CNS relapses are common if no adequate CNS prophylaxis is given (\~ 30% of patients in CR, and up to 75% in patients with R/R disease) \[[@CR123]--[@CR126]\]. Therefore, all current ALL regimens include CNS prophylaxis. The method of prophylaxis has varied according to the regimen being used, including intrathecal (IT) chemotherapy, high dose systemic therapy, radiation, or a combination of them. Efforts have been made to lower the doses or completely omit prophylactic cranial irradiation due to its significant cognitive toxicity, especially for long-term survivors. The combination of effective high-dose systemic therapy with CNS penetration (e.g., methotrexate or cytarabine) with IT chemotherapy has been equally effective, with CNS recurrence incidence of \< 6%, similar to what is seen in regimens that used cranial radiation \[[@CR127], [@CR128]\]. Furthermore, one meta-analysis showed that cranial radiation in contemporary protocols was beneficial only in patients with overt CNS disease \[[@CR129]\]. IT chemotherapy prophylaxis is typically given with alternating doses of methotrexate and cytarabine. The number of IT chemotherapy depends on the predetermined disease risk \[[@CR128], [@CR130]\]. For instance, the HCVAD regimen employs 8 IT chemotherapy doses for standard risk B or T cell ALL, 12 for Ph-positive ALL, and 16 for Burkitt leukemia, a risk-adapted approach that has resulted in a CNS recurrence rate \< 4% \[[@CR131]\].

Incorporation of MRD into therapeutic decision-making {#Sec23}
=====================================================

Despite high remission rates with frontline chemotherapy, unfortunately at least 40% of adults with ALL eventually relapse. This has been attributed mainly to the persistence of relatively chemoresistant MRD, which is low level of disease that is below the detection threshold of standard cyto-morphological assessment. MRD has refined risk stratification in ALL, as early clearance of MRD is reflective of high sensitivity to therapy and correlates with excellent long-term outcomes. Multiple retrospective and prospective studies have demonstrated that clearance of MRD at the end of induction or early consolidation is the strongest single prognostic factor in ALL, trumping all other predefined standard prognostic factors, such as white blood cells count and cytogenetics \[[@CR8], [@CR132]--[@CR136]\]. This was confirmed in a large meta-analysis of more than 13,000 patients from 39 studies in both pediatric and adult populations \[[@CR7]\]. However, although most patients who are MRD positive will eventually relapse, not all of them do, and, conversely, many relapses occur in MRD-negative patients. This highlights the limitations of current MRD testing, which primarily use multiparameter flow cytometry or polymerase chain reaction (PCR)-based strategies \[[@CR137], [@CR138]\]. Next-generation sequencing (NGS) and digital droplet PCR are other novel promising techniques with higher sensitivity (down to 10^−6^) that are being explored, but they are not standardized yet \[[@CR139]\].

Consensus guidelines recommend MRD assessment to be done after induction, in early consolidation (after approximately 3 months of therapy), and every 3 months thereafter. MRD assessment should also be performed prior to HSCT \[[@CR140]\]. Regardless of the method used (flow cytometry, PCR, NGS), a minimum sensitivity of 10^−4^ is recommended for adequate MRD assessment. In Ph-positive ALL, PCR for *BCR-ABL1* rearrangement is the preferred method of MRD monitoring. Although the optimal timing of MRD assessment is treatment-dependent, the earlier achievement of MRD (e.g., at end of induction) has generally been associated with better outcomes than MRD negativity achieved later over the course of therapy \[[@CR138], [@CR141]\]. MRD detection and monitoring has not only prognostic but also therapeutic implications. Patients with MRD positivity derive benefit from HSCT; however, the outcome of these patients post-HSCT remains suboptimal \[[@CR135], [@CR136], [@CR142], [@CR143]\]. In addition, blinatumomab has shown great efficacy in patients with MRD-positive disease. The phase 2 BLAST study treated 116 patients with blinatumomab who had persistent or recurrent MRD (detectable level of ≥ 0.1%) after chemotherapy. The MRD clearance rate was 80% after 2 cycles of blinatumomab \[[@CR15]\]. The 4-year OS rate was 45%, which compares favorably to expectations of outcomes in MRD-positive patients (\~ 30%) \[[@CR7], [@CR133], [@CR144]\]. This has led to the approval of blinatumomab for this indication, the first such approval of an MRD-directed therapy \[[@CR145]\]. However, new questions have emerged regarding optimal therapy following MRD clearance with blinatumomab such as the role of HSCT, or the relative benefit of TKI in MRD+ in Ph-positive ALL. The efficacy of InO for MRD-positive B cell ALL is also currently being evaluated in two clinical trials (NCT03610438 and NCT03441061).

Evolving role of hematopoietic stem cell transplantation {#Sec24}
========================================================

Historically, nearly all patients with ALL were considered to have high relapse risk, and allogeneic HSCT was offered as consolidation for all fit candidates with suitable donors. Over the past two decades, the unprecedented progress in our understanding of disease biology and the improvement of frontline and salvage therapies have resulted in more accurate risk stratification, which is now primarily based on unique biological features (cytogenetics, genomic, and MRD status). This has allowed for better refinement of consolidative strategies in CR1, and thus HSCT is now largely reserved only for select patients with high-risk disease. Adverse risk cytogenetic features in adults include low hypodiploidy/near triploidy, t(4;11) \[*KMT2A* rearrangement\], complex karyotype (≥ 5 abnormalities), and Ph-like ALL all of which are indications for HSCT in CR1 \[[@CR89], [@CR146], [@CR147]\]. Among T cell ALL, the ETP subtype and the lack of *NOTCH1* or *FBXW7* mutations are high-risk subgroups that may derive benefit from HSCT in CR1 \[[@CR101], [@CR148]\]. The presence of *NRAS/KRAS* mutations or *PTEN* gene alteration are other high-risk molecular features among T cell ALL \[[@CR134]\]. However, there are no definitive data on the effect of HSCT in these subgroups \[[@CR89], [@CR149]\].

The advent of MRD assessment has refined the treatment landscape of ALL. Persistent MRD is generally considered an indication for HSCT in CR1 \[[@CR106], [@CR135], [@CR136], [@CR140], [@CR146]\]. However, outcomes remain poor for patients with MRD positivity even when HSCT is performed. It is currently unclear whether patients who clear their MRD with blinatumomab or other novel agents would still derive benefit from HSCT. A post hoc analysis of the BLAST trial showed no difference in RFS or OS rates between patients who underwent HSCT after receiving blinatumomab and those who did not \[[@CR15]\]. However, numbers were small and the equivalent survival outcome may be explained, at least partly, by the fact that HSCT-related mortality may offset the decreased relapse risk seen with HSCT. Furthermore, the role of consolidative HSCT after CAR T cell therapy remains controversial despite being favored by most experts, especially in HSCT-naive and fit patients \[[@CR150]\].

In Ph-positive ALL, the added benefit of HSCT with the achievement of deep molecular remissions with more potent TKIs is now being questioned. We have previously shown that among patients treated with HCVAD plus a TKI without HSCT, the 4-year OS rate is 66% in patients who achieve CMR at 3 months, suggesting that HSCT may not be needed for those patients \[[@CR67]\]. For example, the 5-year OS survival of patients treated with HCVAD plus ponatinib who did not undergo HSCT was 83% in the most recent update \[[@CR57]\]. In contrast, patients who do not achieve at least MMR may benefit from HSCT in CR1 \[[@CR68]\]. When imatinib was combined with HCVAD or a lower-intensity version of HCVAD in a randomized fashion, the benefit of HSCT was restricted to patients who did not achieve MMR after 2 cycles \[[@CR11]\]. Taken together, these findings suggest that patients with Ph-positive ALL who achieve early deep molecular remissions may have excellent long term outcomes and may potentially be spared the toxicity of HSCT.

Moreover, the recent advance of haploidentical donor HSCT, has improved transplant-related outcomes for adults with ALL, especially older patients who are more likely to lack a matched donor \[[@CR151]--[@CR153]\]. This may be a particularly good option for patients with MRD-positive disease, as one prospective study showed better outcomes for haploidentical donor HSCT compared with matched sibling donor HSCT in this context \[[@CR154]\]. In addition, the acceptable non-relapse mortality and favorable survival seen in patients older than 60 years treated with reduced-intensity conditioning (with post-HSCT OS up to 45% reported in this population) have made allogeneic HSCT a more feasible approach for older/less fit patients \[[@CR155]--[@CR157]\]. As both HSCT and non-HSCT options for ALL are rapidly evolving, decisions regarding indications for HSCT and proper patient selection are becoming increasingly complex.

Conclusions and future directions {#Sec25}
=================================

The outcome of adults with ALL remains suboptimal with cure rates of less than 60% in most subtypes. However, a better understanding of the disease biology has generated important knowledge on the prognostic and predictive value of MRD, which has helped guide our treatment strategies, such as intensification or referral to HSCT, the use of MRD-directed novel agents or even treatment de-escalation. We summarize in Fig. [1](#Fig1){ref-type="fig"} our current MRD-based approach to treating ALL in adults. Undoubtedly this algorithm will continue to evolve. Fig. 1Proposed treatment algorithm of adult ALL according to MRD status. ALL, acute lymphoblastic leukemia; MRD, measurable residual disease; Ph, Philadelphia-chromosome; HSCT, hematopoietic stem cell transplant; CMR, complete molecular response; TKI, tyrosine kinase inhibitor; ETP, early T cell precursor

Although the management of ALL is currently moving at an unprecedented pace, many challenges still remain. In Ph-positive ALL, with the dramatic improvement in outcomes by incorporating TKIs and the importance of monitoring MRD, the goal has become the achievement of early molecular remissions (MMR or, preferably, CMR within 3 months). A phase 3 randomized study is currently comparing reduced-intensity chemotherapy combination with either imatinib or ponatinib, which may help to clarify the optimal TKI to use in the frontline setting ([NCT03589326](http://clinicaltrials.gov/show/NCT03589326)). Whether using more potent TKIs such as ponatinib with minimal chemotherapy and/or blinatumomab may produce outcomes that are at least as good and less toxic than intensive chemotherapy-based regimens is yet to be determined. The combination of venetoclax with ponatinib and steroids is also being investigated in R/R Ph-positive ALL (NCT03576547).

With regards to CAR T cell therapy, more data in adult patients and strategies to improve availability of cells and their safety profile are needed. "Off-the-shelf, ready-to-use" allogeneic CAR T cells may overcome the logistical challenge of delivery time \[[@CR158]\] and are currently being investigated (NCT02799550). Furthermore, despite the high rates of remission and MRD negativity, many responses are not durable and relapses occur in \~ 50%, including CD19-negative relapses. Due to the universal expression of CD22 in B cell ALL cells, new strategies to improve CAR T cell outcomes may include CAR-T cells directed against CD22 \[[@CR159]\], and CD19/CD22 dual-targeted constructs \[[@CR160], [@CR161]\]. Most recently, allogeneic CD19 CAR-NK cells have shown high efficacy and minimal toxicity in R/R chronic lymphocytic leukemia and B cell lymphoma \[[@CR162]\]. However, their role in the treatment of ALL is uncertain at the present time.

Unfortunately, there continue to be some high-risk subtypes of ALL such as Ph-like, *KMT2A*-rearrangement, and T cell ALL (particularly ETP ALL), in which progress has lagged behind and thus are in crucial need of novel therapeutic strategies. Based on pre-clinical evidence of high expression of CD38 in T cells, daratumumab, a human moAb against CD38 approved in multiple myeloma, has shown a significant anti-leukemic effect in small case series of R/R T cell ALL and Ph-positive ALL \[[@CR163], [@CR164]\] and is being evaluated in a phase 2 clinical trial (NCT03384654). CAR T cell products against T cell ALL are also in development, although their construction has been more challenging than for B cell ALL. Barriers include difficulty in harvesting an adequate number of autologous T cells and the fratricide (self-killing) effect due to shared antigens between CAR T cells, normal T cells, and leukemic T cells, such as CD7 which is present in \~ 95% of T cell ALL \[[@CR165]\]. One emerging way to overcome these hurdles is CRISPR/Cas9 editing to delete CD7 from healthy "off-the-shelf" donor T cells while transducing them with CD7 targeting CAR. The early results of this approach are promising \[[@CR166]\]. In an interim analysis of a phase I study of CD7 CAR T cells for R/R T cell ALL, all 5 patients treated (median age 24 years and median of 5 prior lines of therapy) achieved CR, with only 1 of them relapsing after a median follow-up of 3 months. No CRS or graft-versus disease was seen.

With the development of novel, effective therapies such as InO, blinatumomab, and CAR T cells, our treatment options have not only expanded, but our focus is shifting toward strategies that minimize cytotoxic chemotherapy and HSCT. However, until the best combination and sequence of these novel agents are fully defined, enrollment in clinical trials, and referral to tertiary centers remains crucial. With continued efforts to optimize the available therapies with novel combinations, there is reason for optimism that the treatment of adult ALL may eventually become another oncological success story.
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